Breaking News Instant updates and real-time market news.

TBPH

Theravance Biopharma

$29.38

1.24 (4.41%)

, GSK

GlaxoSmithKline

$36.82

0.36 (0.99%)

08:43
02/15/18
02/15
08:43
02/15/18
08:43

Theravance Biopharma reports submission of Trelegy Ellipta study to EMA

Theravance Biopharma (TBPH) reported the submission of the IMPACT study data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease. Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single Ellipta inhaler. If this latest submission is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva, formerly Theravance, Inc. Theravance Biopharma is entitled to receive an 85% economic interest in the royalties paid by GSK on worldwide net sales. Theravance Biopharma is not responsible for any costs related to Trelegy Ellipta.

TBPH

Theravance Biopharma

$29.38

1.24 (4.41%)

GSK

GlaxoSmithKline

$36.82

0.36 (0.99%)

  • 25

    Mar

  • 23

    Apr

  • 13

    Nov

TBPH Theravance Biopharma
$29.38

1.24 (4.41%)

08/16/17
EVER
08/16/17
INITIATION
Target $45
EVER
Outperform
Theravance Biopharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Theravance Biopharma with an Outperform and a $45 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $55
CANT
Overweight
Theravance Biopharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Theravance Biopharma with an Overweight rating and $55 price target.
05/10/17
LEER
05/10/17
NO CHANGE
Target $47
LEER
Outperform
Theravance Biopharma price target raised to $47 from $34 at Leerink
Leerink analyst Geoffrey Porges raised his price target Theravance Biopharma to $47 from $34 after the company reported Q1 financial results and provided an update for investors about its development progress and upcoming milestones. The analyst reiterates an Outperform rating on the shares.
03/29/17
PIPR
03/29/17
NO CHANGE
Target $42
PIPR
Overweight
Mylan news a positive for Theravance, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Mylan's (MYL) complete response letter for its generic version of GlaxoSmithKline's Advair "buys time and will likely preserve some pricing power in the broader respiratory space." This will be important for GSK's commercialization of the closed triple following potential regulatory approval at year end, Schimmer tells investors in a research note. This is also positive for Theravance Biopharma (TBPH), which stands to receive a "meaningful" mid/high single digit royalty on the closed triple, the analyst contends. He reiterates an Overweight rating on Theravance with a $42 price target. The stock is up 49c to $36.47 in afternoon trading.
GSK GlaxoSmithKline
$36.82

0.36 (0.99%)

02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.
01/16/18
LEHM
01/16/18
UPGRADE
LEHM
Overweight
GlaxoSmithKline upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis upgraded GlaxoSmithKline to Overweight from Equal Weight and raised his price target for the shares to GBP 16.50 from GBP 14.50. The analyst believes concerns are now reflected in the valuation and consensus expectations while HIV and shingles offer "sustainable drivers of mid-term growth."

TODAY'S FREE FLY STORIES

06:55
12/14/18
12/14
06:55
12/14/18
06:55
General news
Oil action: Front-month WTI crude prices are down 0.7% »

Oil action: Front-month…

WEI

Weidai

$10.00

-0.14 (-1.38%)

06:52
12/14/18
12/14
06:52
12/14/18
06:52
Initiation
Weidai initiated  »

Weidai initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$256.24

-2.055 (-0.80%)

06:51
12/14/18
12/14
06:51
12/14/18
06:51
Hot Stocks
NeoTract: 12-month results from study of UroLift System published »

NeoTract, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$114.87

0.51 (0.45%)

06:51
12/14/18
12/14
06:51
12/14/18
06:51
Hot Stocks
Eli Lilly expands collaboration with Evidation Health for Andromeda platform »

Eli Lilly and Evidation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

SBUX

Starbucks

$66.90

0.8 (1.21%)

06:50
12/14/18
12/14
06:50
12/14/18
06:50
Recommendations
Starbucks analyst commentary  »

Starbucks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DEA

Easterly Government Properties

$17.41

0.03 (0.17%)

06:50
12/14/18
12/14
06:50
12/14/18
06:50
Upgrade
Easterly Government Properties rating change  »

Easterly Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$78.44

0.95 (1.23%)

06:47
12/14/18
12/14
06:47
12/14/18
06:47
Hot Stocks
Merck to acquire Antelliq Group for approximately EUR2.1B »

Merck and privately held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 16

    Feb

SBUX

Starbucks

$66.90

0.8 (1.21%)

06:46
12/14/18
12/14
06:46
12/14/18
06:46
Recommendations
Starbucks analyst commentary  »

Starbucks' LT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

MRK

Merck

$78.44

0.95 (1.23%)

06:45
12/14/18
12/14
06:45
12/14/18
06:45
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck to acquire Antelliq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 16

    Feb

LSCC

Lattice Semiconductor

$6.63

-0.05 (-0.75%)

06:45
12/14/18
12/14
06:45
12/14/18
06:45
Upgrade
Lattice Semiconductor rating change  »

Baird upgrades Lattice to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$21.35

0.11 (0.52%)

06:44
12/14/18
12/14
06:44
12/14/18
06:44
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

06:43
12/14/18
12/14
06:43
12/14/18
06:43
Recommendations
Adobe analyst commentary  »

Adobe price target cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.60

0.09 (0.16%)

06:41
12/14/18
12/14
06:41
12/14/18
06:41
Recommendations
Carnival analyst commentary  »

Nomura sees 30% total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 20

    Dec

DLTR

Dollar Tree

$85.04

0.45 (0.53%)

06:38
12/14/18
12/14
06:38
12/14/18
06:38
Upgrade
Dollar Tree rating change  »

Dollar Tree upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

06:37
12/14/18
12/14
06:37
12/14/18
06:37
Recommendations
Adobe analyst commentary  »

Adobe price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$21.35

0.11 (0.52%)

06:36
12/14/18
12/14
06:36
12/14/18
06:36
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARE

Alexandria Real Estate

$123.00

1.88 (1.55%)

06:36
12/14/18
12/14
06:36
12/14/18
06:36
Upgrade
Alexandria Real Estate rating change  »

Alexandria Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

SU

Suncor

$30.67

-0.31 (-1.00%)

06:35
12/14/18
12/14
06:35
12/14/18
06:35
Hot Stocks
Suncor announces 2019 capital program of $4.9B-$5.6B »

Suncor released its 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$31.84

-0.22 (-0.69%)

06:35
12/14/18
12/14
06:35
12/14/18
06:35
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$135.56

-2.25 (-1.63%)

, WDC

Western Digital

$39.95

-1.01 (-2.47%)

06:34
12/14/18
12/14
06:34
12/14/18
06:34
Hot Stocks
Autodesk adds Western Digital CEO Stephen Milligan to board »

Autodesk (ADSK) announced…

ADSK

Autodesk

$135.56

-2.25 (-1.63%)

WDC

Western Digital

$39.95

-1.01 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$34.90

2.765 (8.60%)

06:34
12/14/18
12/14
06:34
12/14/18
06:34
Recommendations
Ciena analyst commentary  »

Ciena price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CODX

Co-Diagnostics

$2.20

(0.00%)

06:32
12/14/18
12/14
06:32
12/14/18
06:32
Hot Stocks
Co-Diagnostics awarded UK patent for RapidProbe probe technology »

Co-Diagnostics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$47.46

0.03 (0.06%)

06:31
12/14/18
12/14
06:31
12/14/18
06:31
Downgrade
Cisco rating change  »

Nomura downgrades Cisco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 10

    Jan

  • 04

    Mar

DB

Deutsche Bank

$8.87

-0.16 (-1.77%)

06:31
12/14/18
12/14
06:31
12/14/18
06:31
Periodicals
U.S. lawmakers call for additional 'scrutiny' of Deutsche Bank, WSJ says »

U.S. officials on Capitol…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWR

Genesee & Wyoming

$77.80

-3.01 (-3.72%)

06:31
12/14/18
12/14
06:31
12/14/18
06:31
Hot Stocks
Genesee & Wyoming reports November traffic of 259,000 carloads, down 4.4% y/y »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.